TG Therapeutics, Inc.

Symbol: TGTX

NASDAQ

15.21

USD

Market price today

  • 60.0495

    P/E Ratio

  • 3.7877

    PEG Ratio

  • 2.35B

    MRK Cap

  • 0.00%

    DIV Yield

TG Therapeutics, Inc. (TGTX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.93%

Operating Profit Margin

0.17%

Net Profit Margin

0.14%

Return on Assets

0.11%

Return on Equity

-0.06%

Return on Capital Employed

0.18%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Michael S. Weiss Esq.
Full-time employees:264
City:New York
Address:2 Gansevoort Street
IPO:2010-05-03
CIK:0001001316

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

General Outlook

When we look at how much money they make before expenses, they keep 0.935% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.167%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.142%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.110% return, is a testament to TG Therapeutics, Inc.'s adeptness in optimizing resource deployment. TG Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.059%. Furthermore, the proficiency of TG Therapeutics, Inc. in capital utilization is underscored by a remarkable 0.177% return on capital employed.

Stock Prices

TG Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $18, while its low point bottomed out at $14.87. This variance in figures offers investors a lucid insight into the roller-coaster ride that is TG Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing TGTX liquidity ratios reveals its financial health of the firm. The current ratio of 218.20% gauges short-term asset coverage for liabilities. The quick ratio (283.39%) assesses immediate liquidity, while the cash ratio (-218.20%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio218.20%
Quick Ratio283.39%
Cash Ratio-218.20%

Profitability Ratios

TGTX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 14.38% underscores its earnings before tax deductions. The effective tax rate stands at 9.42%, revealing its tax efficiency. The net income per EBT, 98.99%, and the EBT per EBIT, 86.06%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 16.71%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin14.38%
Effective Tax Rate9.42%
Net Income per EBT98.99%
EBT per EBIT86.06%
EBIT per Revenue16.71%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.18, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a -2 cash conversion cycle and 445.25% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding283
Days of Inventory Outstanding1502
Operating Cycle1583.77
Cash Conversion Cycle1584
Receivables Turnover4.45
Inventory Turnover0.24
Fixed Asset Turnover36.60
Asset Turnover0.78

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.14, and free cash flow per share, 0.14, depict cash generation on a per-share basis. The cash per share value, 1.49, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.07, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.14
Free Cash Flow per Share0.14
Cash per Share1.49
Operating Cash Flow Sales Ratio0.07
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio1.96
Short Term Coverage Ratio14.67

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.77%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.29%, and total debt to capitalization, 6.05%, ratios shed light on its capital structure. An interest coverage of 4.01 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.77%
Debt Equity Ratio0.06
Long Term Debt to Capitalization5.29%
Total Debt to Capitalization6.05%
Interest Coverage4.01
Cash Flow to Debt Ratio1.96
Company Equity Multiplier2.33

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.65, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.09, reflects the portion of profit attributed to each share. The book value per share, 1.13, represents the net asset value distributed per share, while the tangible book value per share, 1.13, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.65
Net Income Per Share0.09
Book Value Per Share1.13
Tangible Book Value Per Share1.13
Shareholders Equity Per Share1.13
Interest Debt Per Share0.80

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 8290.02%, indicates top-line expansion, while the gross profit growth, 8594.76%, reveals profitability trends. EBIT growth, 110.70%, and operating income growth, 110.70%, offer insights into operational profitability progression. The net income growth, 106.22%, showcases bottom-line expansion, and the EPS growth, 105.91%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth8290.02%
Gross Profit Growth8594.76%
EBIT Growth110.70%
Operating Income Growth110.70%
Net Income Growth106.22%
EPS Growth105.91%
EPS Diluted Growth105.65%
Weighted Average Shares Growth4.83%
Weighted Average Shares Diluted Growth9.67%
Operating Cash Flow Growth82.17%
Free Cash Flow Growth82.17%
10-Year Revenue Growth per Share27352.29%
5-Year Revenue Growth per Share81623.97%
3-Year Revenue Growth per Share124796.33%
10-Year Operating CF Growth per Share48.04%
5-Year Operating CF Growth per Share87.05%
3-Year Operating CF Growth per Share88.10%
10-Year Net Income Growth per Share111.08%
5-Year Net Income Growth per Share103.88%
3-Year Net Income Growth per Share103.60%
10-Year Shareholders Equity Growth per Share-28.26%
5-Year Shareholders Equity Growth per Share255.00%
3-Year Shareholders Equity Growth per Share-74.89%
Asset Growth70.27%
Book Value per Share Growth110.03%
Debt Growth33.39%
R&D Expense Growth-32.05%
SGA Expenses Growth46.92%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,442,455,312.96, captures the company's total value, considering both debt and equity. Income quality, -2.48, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.58, gauges operational efficiency, while the research and development to revenue, 32.61%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value2,442,455,312.96
Income Quality-2.48
Sales General and Administrative to Revenue0.58
Research and Development to Revenue32.61%
Intangibles to Total Assets0.24%
Stock-Based Compensation to Revenue16.23%
Graham Number1.51
Return on Tangible Assets3.85%
Graham Net Net0.75
Working Capital264,223,000
Tangible Asset Value159,703,000
Net Current Asset Value148,858,000
Invested Capital1
Average Receivables25,546,500
Average Payables40,245,000
Average Inventory19,911,500
Days Sales Outstanding80
Days Payables Outstanding965
Days of Inventory On Hand999
ROIC7.64%
ROE0.08%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 15.41, and the price to book ratio, 15.41, reflect the market's valuation relative to the company's book value. The price to sales ratio, 9.04, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 128.93, and price to operating cash flows, 121.97, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio15.41
Price to Book Ratio15.41
Price to Sales Ratio9.04
Price Cash Flow Ratio121.97
Price Earnings to Growth Ratio3.79
Enterprise Value Multiple48.50
Price Fair Value15.41
Price to Operating Cash Flow Ratio121.97
Price to Free Cash Flows Ratio128.93
Price to Tangible Book Ratio15.11
Enterprise Value to Sales10.45
Enterprise Value Over EBITDA116.00
EV to Operating Cash Flow-77.75
Earnings Yield0.52%
Free Cash Flow Yield-1.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of TG Therapeutics, Inc. (TGTX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 60.050 in 2024.

What is the ticker symbol of TG Therapeutics, Inc. stock?

The ticker symbol of TG Therapeutics, Inc. stock is TGTX.

What is company IPO date?

IPO date of TG Therapeutics, Inc. is 2010-05-03.

What is company current share price?

Current share price is 15.210 USD.

What is stock market cap today?

The market cap of stock today is 2348743410.000.

What is PEG ratio in 2024?

The current 3.788 is 3.788 in 2024.

What is the number of employees in 2024?

In 2024 the company has 264.